IP Verse

Treatment Of Age Related Macular Degeneration With A Small Active Choroidal Neovascularization Lesion - EP3230316

The patent EP3230316 was granted to Bayer Healthcare on Jan 5, 2022. The application was originally filed on Dec 10, 2015 under application number EP15819965A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3230316

BAYER HEALTHCARE
Application Number
EP15819965A
Filing Date
Dec 10, 2015
Status
Granted And Under Opposition
Dec 3, 2021
Grant Date
Jan 5, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AMGENOct 5, 2022UEXKULL & STOLBERGADMISSIBLE
BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBBOct 5, 2022KUTTENKEULERADMISSIBLE
BOULT WADE TENNANTOct 5, 2022-ADMISSIBLE
MAIWALDOct 5, 2022MAIWALDWITHDRAWN
WITHERS & ROGERSOct 4, 2022POHLMANADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBOct 4, 2022WICHMANNADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO0075319
DESCRIPTIONWO2007112675
DESCRIPTIONWO9818480
DESCRIPTIONWO9845331
INTERNATIONAL-SEARCH-REPORTWO02062386
OPPOSITIONWO2016094673

Non-Patent Literature (NPL) Citations (82) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- ALTAWEEL MICHAEL ET AL, "Clinical Outcomes of Eyes with Neovascular Lesions Composed of > 50% Blood Treated with Anti-VEGF Therapy in the Comparison of AMD Treatments Trials (CATT)", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (201306), Database accession no. PREV201800956959, XP002805783-
EXAMINATION- ALTAWEEL MICHAEL M ET AL, "Outcomes of Eyes with Lesions Composed of > 50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)", OPHTHALMOLOGY, (201502), vol. 122, no. 2, ISSN 0161-6420(print), pages 391 - 398-
EXAMINATION- IOVS, ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPHTHALMOLOGY (ARVO); SEATTLE, WA, USA; MAY 05 -09, 2013, (201306), vol. 54, no. 15, ISSN 0146-0404(print), page 4162-
EXAMINATION- BEAUMONT PAUL E ET AL, "Lesion morphology in age-related macular degeneration and its therapeutic significance", ARCHIVES OF OPHTHALMOLOGY, (200606), vol. 124, no. 6, doi:10.1001/archopht.124.6.807, ISSN 0003-9950, pages 807 - 812, XP055895136
EXAMINATION- Robert P. Finger ET AL, "Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration", SURVEY OF OPHTHALMOLOGY., XX, (20140101), vol. 59, no. 1, doi:10.1016/j.survophthal.2013.03.009, ISSN 0039-6257, pages 1 - 18, XP055495272
EXAMINATION- OHR MATTHEW ET AL, "Aflibercept in wet age-related macular degeneration: a perspective review.", THERAPEUTIC ADVANCES IN CHRONIC DISEASE JUL 2012, (201207), vol. 3, no. 4, doi:10.1177/2040622312446007, ISSN 2040-6223, pages 153 - 161, XP055895121
OPPOSITION- Altaweel, Et Al., "Outcome of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials(CATT)", OPHTHALMOLOGY, (20141009), OPHTHALMOLOGY, (20221017), XP055971647-
OPPOSITION- Andrew A Chang, Haitao Li 2, Geoffrey K Broadhead 3, Thomas Hong 2, Timothy E Schlub 4, Wijeyanthy Wijeyakumar 3, Meidong Zhu, "Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration", Ophthalmology, (20140101), vol. 121, no. 1, pages 188 - 192, XP055973174-
OPPOSITION- Anonymous, "Aflibercept solution for injection for treating wet age-related macular degeneration", Technology appraisal guidance, (20130724), pages 1 - 49, Technology appraisal guidance, URL: https://www.nice.org.uk/guidance/ta294/resources/aflibercept-solution-for-injection-for-treating-wet-agerelated-macular-degeneration-pdf-82600733390533, (20221020), XP055973164-
OPPOSITION- Anonymous, "Age-Related Macular Degeneration: Guidelines for Management", The Royal College of Ophthalmologists, (20130901), pages 1 - 145, XP055973162-
OPPOSITION- Anonymous, "AGE-RELATED MACULAR DEGENERATION PPP ", Preferred Practice Pattern Guidelines, (20140101), Preferred Practice Pattern Guidelines, (20221018), XP055972192-
OPPOSITION- Anonymous, "age related macular degeneration services ", the royal college of ophthalmologists, (20210601), the royal college of ophthalmologists , (20221018), XP055972154-
OPPOSITION- Anonymous, "ELYEA ASSESSMENT REPORT ", EUROPEAN MEDICINES AGENCY (EMA, (20120920), XP055972207-
OPPOSITION- Anonymous, "Guidelines of the German Ophthalmological Society on anti-VEGF therapy in neovascular age-related macular degeneration", BVA, (20141101), XP055972188-
OPPOSITION- Anonymous, "Highlights of Prescribing information EYLEA", FDA, (20140101), FDA, (20221016), XP055971644-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - EYLEA™ (aflibercept) Injection", Regeneron Pharmaceuticals, Inc., (20111101), pages 1 - 15, XP055895379-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EYLEA safely and effectively. ", FDA, (20111101), FDA, (20221018), XP055972290-
OPPOSITION- Anonymous, "History of Changes for Study: NCT00320788 Safety and Efficacy of Repeated lntravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)", ClinicalTrials.gov, (20120127), XP055972280-
OPPOSITION- Anonymous, "History of Changes for Study: NCT01482910 VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (AgeRelated Macular Degeneration)", ClinicalTrials.gov, (20160928), XP055972288-
OPPOSITION- Anonymous, "History of Changes for Study: NCT02305238 Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration (ALTAIR)", CLINICAL TRIALS GOV, (20181220), CLINICAL TRIALS GOV , (20221018), XP055972224-
OPPOSITION- Anonymous, "Laser Photocoagulation of Subfoveal Recurrent Neovascular Lesions in Age-Related Macular Degeneration Results of a Randomized Clinical Trial ", ARCH OPHTHALMOL., (19910901), pages 1232 - 1241, XP055972167-
OPPOSITION- Anonymous, "Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration", N Engl J Med, (20110519), vol. 364, no. 20, pages 1897 - 1908, XP055972148-
OPPOSITION- Anonymous, "Ranibizumab and pegaptanib for the treatment of age- related macular degeneration", Technology appraisal guidance, (20080827), pages 1 - 44, Technology appraisal guidance , URL: https://www.nice.org.uk/guidance/ta155/resources/ranibizumab-and-pegaptanib-for-the-treatment-of-agerelated-macular-degeneration-pdf-82598316423109, (20221020), XP055973169-
OPPOSITION- Anonymous, "Ranibizumab and pegaptanib for the treatment of age- related macular degeneration", Technology appraisal guidance, (20080827), pages 1 - 44, URL: https://www.nice.org.uk/guidance/ta155/resources/ranibizumab-and-pegaptanib-for-the-treatment-of-agerelated-macular-degeneration-pdf-82598316423109, XP055973169-
OPPOSITION- Anonymous, "Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)", ClinicalTrials.gov, (20120301), pages 1 - 8, ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT00320788, (20221020), XP055973144-
OPPOSITION- Bozho Todorich, Prithvi Mruthyunjaya, "Pigment Epithelial Detachments and Age-Related Macular Degeneration", (20140101), pages 1 - 5, URL: https://www.visioncareprofessional.com/emails/amdupdate/index65.htm, (20221020), XP055973155-
OPPOSITION- Cerrada-Gimenez Marc, Vähätupa Maria, Lappeteläinen Birgitta, Tähtivaara Leena, Jokinen Ville, Haapaniemi Anne Mari, Vergun Olga, Kvietkauskiene Nerija, Bijeikis Simas, Jarutis Jonas, Kolehmainen Anni, Mertano Pinja, Sarkola Emmi, Kalesnykas Giedrius, Kaja Simon, "Suprachoroidal administration of aflibercept protects against neovascularization in the mouse CNV model", ARVO Journals, (20230601), ARVO Journals, URL: https://iovs.arvojournals.org/article.aspx?articleid=2790117, XP093297277-
OPPOSITION- Domalpally A., Et Al., "Fluorescein Angiography in Neovascular AMD", REVIEW OF OPHTHALMOLOGY, (20080825), REVIEW OF OPHTHALMOLOGY, (20221016), XP055971635-
OPPOSITION- Domalpally A., et al., "Fluorescein Angiography in Neovascular AMD", REVIEW OF OPHTHALMOLOGY, (20080825), XP055971635-
OPPOSITION- FDA, "EYLEA™", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20111101), XP055972290-
OPPOSITION- Gui-Shuang Ying,, Benjamin J. Kim, Md; Maureen G. Maguire, Phd; Jiayan Huang, Ms; Ebenezer Daniel, Phd; Glenn J. Jaffe, Md; Juan E. Grunwald, Md; Kevin J. Blinder, Md; Christina J. Flaxel, Md; Firas Rahhal, Md; Carl Regillo, Md; Daniel F. Martin, Md; For The Catt Research Group, "Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials", JAMA Ophthalmol., vol. 132, no. 8, pages 915 - 921, XP055972127-
OPPOSITION- Ho Allen, Et Al., "Age-related Macular Degeneration Diagnosis and Treatment", (20110101), pages 90 - 92, 118, 150, 155, 242, 256, XP055971643-
OPPOSITION- Holz F G, Et Al., "Anti-VEGF-Therapie der AMD: Ergebnisse und Leitlinien", Altersabhjngige Makuladegeneration, (20110101), Altersabhjngige Makuladegeneration, (20221016), XP055971646-
OPPOSITION- Jeffrey S. Heier,, Andrew N. Antoszyk, Md,2 Peter Reed Pavan, Md,3 Steven R. Leff, Md,4 Philip]. Rosenfeld, Md, Phd,5 Thomas A. Ciulla, Md,6 Richard F. Dreyer, Md,7 Ronald C. Gentile, Md,8 Judy P. Sy, Phd,9 Gary Hantsbarger, Phd,9 Naveed Shams, Md, Phd9, "Ranibizumab for Treatment of N eovascular Age--Related Macular Degeneration A Phase I/II Multicenter, Controlled, Multidose Study", Ophthalmology, (20060401), vol. 113, no. 4, pages 633 - 642, XP055972112-
OPPOSITION- Lu X, Et Al., "Profile of conbercept in the treatment of neovascular age-related macular degeneration", DRUG DESIGN, DEVELOPMENT AND THERAPY2311, (20150101), vol. 9, XP055971636-
OPPOSITION- MACULAR PHOTOCOAGULATION STUDY GROUP, "Subfoveal Neovascular Lesions in Age- Related Macular Degeneration", Arch Ophthalmol, (19910000), vol. 109, pages 1242 - 1257, XP009140730-
OPPOSITION- MACULAR PHOTOCOAGULATION STUDY GROUP (USA), "SUBFOVEAL NEOVASCULAR LESIONS IN AGE-RELATED MACULAR DEGENERATION GUIDELINES FOR EVALUATION AND TREATMENT IN THE MACULAR PHOTOCOAGULATION STUDY", Archives of Ophthalmology, American Medical Association, United States, United States , (19910901), vol. 109, no. 9, ISSN 0003-9950, pages 1242 - 1257, XP009140730-
OPPOSITION- MACULAR PHOTOCOAGULATION STUDY GROUP (USA), "SUBFOVEAL NEOVASCULAR LESIONS IN AGE-RELATED MACULAR DEGENERATION GUIDELINES FOR EVALUATION AND TREATMENT IN THE MACULAR PHOTOCOAGULATION STUDY", Archives of Ophthalmology, United States , (19910901), vol. 109, no. 9, ISSN 0003-9950, pages 1242 - 1257, XP009140730-
OPPOSITION- Mckibbin M Gb Com, Devonpoort H., Gale R., Gavin M., Lotery A., Mahmood S., Patel P.J., Ross A., Sivaprasad S., Talks J., Walters G., "Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel", Eye, (20150701), vol. 29, no. suppl. 1, pages S1 - S11, XP055973584-
OPPOSITION- Miguel Hage Amaro, Aaron Brock Roller , "Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic astrophy ", Arq Bras Oftalmol, (20120101), vol. 75, no. 4, pages 273 - 276, XP055972108-
OPPOSITION- Paul Hahn, "Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye", Clinical Ophthalmology, (20140101), vol. 8, pages 2129 - 2131, XP055972120-
OPPOSITION- Sandrine A Zweifel; Christoph Amstutz; Johannes Fleischhauer; Malaika Kurz-Levin; Daniel Barthelmes, "Preliminary results of aflibercept in treatment naive choroidal neovascularization of neovascular age-related macular degeneration", Investigative Ophthalmology & Visual Science, vol. 55, (20140400), page 3942, URL: https://iovs.arvojournals.org/article.aspx?articleid=2269413-
OPPOSITION- Semeraro F, Et Al., "Aflibercept in wet AMD: specific role and optimal use", DRUG DESIGN, DEVELOPMENT AND THERAPY, (20130101), vol. 7, XP055971638-
OPPOSITION- Sharma J., Et Al., "Aflibercept - How does it compare with other Anti-VEGF Drugs?", Austin J Clin Ophthalmol, (20140101), page 1016, Austin J Clin Ophthalmol, (20221016), XP055971640-
OPPOSITION- Shiri Zayit-Soudry,, Meirav Alfasi, Md,T Michaella Goldstein, Md,* Joseph Moisseiev, Md,:J:Tt Ruth Axer-Siegel, Md,§tt Ayala Pollack, Md,Ci[** Yuval Yassur, Md,#tt Anat Loewenstein, Md*, "VARIABILITY AMONG RETINA SPECIALISTS IN EVALUATING FLUORFSCEIN ANGIOGRAMS OF PATIENTS WITH NEOV ASCULAR AGERELATED MACULAR DEGENERATION", Retina, (20070101), vol. 27, no. 6, pages 798 - 803, XP055972158-
OPPOSITION- Stefania Miotto~, Nicola Zemella; Elena Gusson~ Giacomo Panozzo; Sandro Saviano;' Giuseppe Scarpa? Giorgio Boschi? Stefano Piermarocchi7, "Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, (20180101), vol. 34, no. 3, pages 298 - 308, XP055972137-
OPPOSITION- Ursula Schmidt,Erfurth,, Peter K. Kaiser, Md,2 Jean,Frar1fois Korobelnik, Md,3 David M. Brown, Md,4 Victor Chong, Md,5 Quan Dong Nguyen, Md,6 Allen C. Ho, Md,7 Yuichiro Ogura, Md,8 Christian Simader, Md, 1 Glenn]. Jaffe, Md,9 Jason S. Slakter, Md, 10 George D. Yancopoulos, Md, Phd, 11 Neil Stahl, Phd, 11 Robert Vitti, Md, 1 Allsonj. Berliner, Md, Phd, 11 Yuhwensoo, Phd, 11 Majidanderesi, Md, 12 Olaf Sowade, Md, 12 Oliver Zeitz, Md, 1 •13 Christiane Norenberg, Ms, 12 Rupert Sandbrink, Md, Phd, 12 •14 Jeffrey S. Heier, Md15, "Intravitreal Aflibercept Injection for N eovascular Age-related Macular Degeneration", OPHTHALMOLOGY, (20140101), vol. 121, no. 1, pages 193 - 201, XP055972253-
OPPOSITION- Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan M Downes, Andrew J Lote,Y, Lucy A Culliford, Barnaby C Reeves, "Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial", THE LANCET, (20131012), vol. 382, pages 1258 - 1267, XP055972176-
OPPOSITION- Wang X, Et Al., "Vascular endothelial growth factor and its inhibitor in age- related macular degeneration", Taiwan Journal of Ophthalmology, (20130101), vol. 3, XP055971641-
OPPOSITION- Xiaoxin Li, Youxin Chen~ Junjun Zhang: Xun Xu; Feng Zhang;' Chui Ming Gemmy Cheung? Rui Yu; Husain Kazmi? Olaf Sowade; Oliver Zeitz9, "lntravitreal Aflibercept Versus Photodynamic Therapy in Chinese Patients with Neovascular Age-Related Macular Degeneration: Outcomes of the SIGHT Study", 6, (20170101), vol. 33, no. 6, pages 435 - 444, XP055972142-
OPPOSITION- Yuichiro Ogura, Hiroko Terasaki,2 Fumi Gomi,3 Mitsuko Yuzawa,4 Tomohiro Lida,5 Miki Honda,6 Koichi Nishijo,7 Olaf Sowade,8 Tetsushi Komori,7 Ursula Schmidt-Erfurth, 9 Christian Simader, 10 Victor Chong, "Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study", Br. J. Ophthalmol., (20150101), vol. 99, pages 92 - 97, XP055972272-
OPPOSITION- Zhang M., Et Al., "A Phase 1 Study of KH902, a Vascular Endothelial Growth Factor Receptor Decoy, for Exudative Age-Related Macular Degeneration", OPHTHALMOLOGY, (20110404), vol. 118, XP055971637-
OPPOSITION- Beaumont Paul E., Franzco, Kang H Kwon, Franzco, "Lesion Morphology in Age-Related Macular Degeneration and Its Therapeutic Significance", Archives of Ophthalmology, American Medical Association, United States, United States , (20060601), vol. 124, no. 6, doi:10.1001/archopht.124.6.807, ISSN 0003-9950, page 807, XP055895136
OPPOSITION- Beaumont Paul E., Franzco, Kang H Kwon, Franzco, "Lesion Morphology in Age-Related Macular Degeneration and Its Therapeutic Significance", Archives of Ophthalmology, United States , (20060601), vol. 124, no. 6, doi:10.1001/archopht.124.6.807, ISSN 0003-9950, page 807, XP055895136
OPPOSITION- Fassnacht-Riederle Heidi, Becker Matthias, Graf Nicole, Michels Stephan, "Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD", Graefe's Archive for Clinical and Experimental Ophthalmology, Springer Berlin Heidelberg, Berlin/Heidelberg, Berlin/Heidelberg, (20141101), vol. 252, no. 11, doi:10.1007/s00417-014-2589-3, ISSN 0721-832X, pages 1705 - 1709, XP055973181
OPPOSITION- Stifter, E. Michels, S. Prager, F. Georgopoulos, M. Polak, K. Hirn, C. Schmidt-Erfurth, U., "Intravitreal Bevacizumab Therapy for Neovascular Age-related Macular Degeneration with Large Submacular Hemorrhage", American Journal of Ophthalmology, AMSTERDAM, NL , (20071121), vol. 144, no. 6, doi:10.1016/j.ajo.2007.07.034, ISSN 0002-9394, pages 886 - 892, XP022356119
OPPOSITION- Kaiser, P.K. Brown, D.M. Zhang, K. Hudson, H.L. Holz, F.G. Shapiro, H. Schneider, S. Acharya, N.R., "Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20071022), vol. 144, no. 6, doi:10.1016/j.ajo.2007.08.012, ISSN 0002-9394, pages 850 - 857.e4, XP022356113
OPPOSITION- Ho Vincent Y., Yeh Steven, Olsen Timothy W., Bergstrom Chris S., Yan Jiong, Cribbs Blaine E., Hubbard G. Baker, "Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated With Other Vascular Endothelial Growth Factor Inhibitors /NIH Author Manuscript/", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20130701), vol. 156, no. 1, doi:10.1016/j.ajo.2013.02.009, ISSN 0002-9394, pages 23 - 28.e2, XP055973191
OPPOSITION- Bakall Benjamin; Folk James C.; Boldt H. Culver; Sohn Elliott H.; Stone Edwin M.; Russell Stephen R.; Mahajan Vinit B., "Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20130522), vol. 156, no. 1, doi:10.1016/j.ajo.2013.02.017, ISSN 0002-9394, pages 15 - 22.e1, XP028571376
OPPOSITION- Yonekawa Yoshihiro; Andreoli Christopher; Miller John B.; Loewenstein John I.; Sobrin Lucia; Eliott Dean; Vavvas Demetrios G.; Miller Joan W.; Kim Ivana K., "Conversion to Aflibercept For Chronic Refractory Or Recurrent Neovascular Age-Related Macular Degeneration", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20130510), vol. 156, no. 1, doi:10.1016/j.ajo.2013.03.030, ISSN 0002-9394, pages 29 - 35, XP028571386
OPPOSITION- Jeffrey S. Heier; David Boyer; Quan Dong Nguyen; Dennis Marcus; Daniel B. Roth; George Yancopoulos; Neil Stahl; Avner Ingerman; Robert Vitti; Alyson J. Berliner; Ke Yang; David M. Brown;, "The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing", Ophthalmology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20110315), vol. 118, no. 6, doi:10.1016/j.ophtha.2011.03.020, ISSN 0161-6420, pages 1098 - 1106, XP028372935
OPPOSITION- J. HEIER et al., "The 1-year results of CLEAR- IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing", Ophthalmology, (20110000), vol. 118, doi:10.1016/j.ophtha.2011.03.020, pages 1098 - 1106, XP028372935
OPPOSITION- Gui-Shuang Ying, Huang Jiayan, Maguire Maureen G., Jaffe Glenn J., Grunwald Juan E., Toth Cynthia, Daniel Ebenezer, Klein Michael, Pieramici Dante, Wells John, Martin Daniel F., "Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration", Ophthalmology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20130101), vol. 120, no. 1, doi:10.1016/j.ophtha.2012.07.042, ISSN 0161-6420, pages 122 - 129, XP055252719
OPPOSITION- Jeffrey S. Heier, David M. Brown, Victor Chong, Jean-Francois Korobelnik, Peter K. Kaiser, Quan Dong Nguyen, Bernd Kirchhof, Allen Ho, Yuichiro Ogura, George D. Yancopoulos, Neil Stahl, Robert Vitti, Alyson J. Berliner, Yuhwen Soo, Majid Anderesi, Georg Groetzbach, Bernd Sommerauer, Rupert Sandbrink, Christian Simader, Ursula Schmidt-Erfurth, "Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration", Ophthalmology, (20121201), vol. 119, no. 12, doi:10.1016/j.ophtha.2012.09.006, ISSN 01616420, pages 2537 - 2548, XP055138976
OPPOSITION- Jeffrey S. Heier, David M. Brown, Victor Chong, Jean-Francois Korobelnik, Peter K. Kaiser, Quan Dong Nguyen, Bernd Kirchhof, Allen Ho, Yuichiro Ogura, George D. Yancopoulos, Neil Stahl, Robert Vitti, Alyson J. Berliner, Yuhwen Soo, Majid Anderesi, Georg Groetzbach, Bernd Sommerauer, Rupert Sandbrink, Christian Simader, Ursula Schmidt-Erfurth, "Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration", Ophthalmology, Elsevier, (20121201), vol. 119, no. 12, doi:10.1016/j.ophtha.2012.09.006, ISSN 01616420, pages 2537 - 2548, XP055138976
OPPOSITION- J. HEIER et al., "Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration", Ophthalmology, (20121200), vol. 119, no. 12, doi:10.1016/j.ophtha.2012.09.006, pages 2537 - 2548, XP055138976
OPPOSITION- Busbee Brandon G., Ho Allen C., Brown David M., Heier Jeffrey S., Suñer Ivan J., Li Zhengrong, Rubio Roman G., Lai Phillip, "Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration", Ophthalmology, AMSTERDAM, NL, (20130501), vol. 120, no. 5, doi:10.1016/j.ophtha.2012.10.014, ISSN 0161-6420, pages 1046 - 1056, XP055971656
OPPOSITION- Busbee Brandon G., Ho Allen C., Brown David M., Heier Jeffrey S., Suñer Ivan J., Li Zhengrong, Rubio Roman G., Lai Phillip, "Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration", Ophthalmology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20130501), vol. 120, no. 5, doi:10.1016/j.ophtha.2012.10.014, ISSN 0161-6420, pages 1046 - 1056, XP055971656
OPPOSITION- Altaweel Michael M., Daniel Ebenezer, Martin Daniel F., Mittra Robert A., Grunwald Juan E., Lai Michael M., Melamud Alexander, Morse Lawrence S., Huang Jiayan, Ferris Frederick L., Fine Stuart L., Maguire Maureen G., Williams David F., Beardsley Sara, Bennett Steven, Cantrill Herbert, Chan- Tram Carmen, Cheshier Holly, Damato Kathyrn, Davies John, Dev Sundeep, Enloe Julianne, Follano Gennaro, Gilbert Peggy, Johnson Jill, Jones Tori, Mayleben Lisa, Moos Martha, Neist Ryan, Oestreich Neal, Quiram Polly, Ramsay Robert, Ryan Edwin, Schindeldecker Stephanie, Snater John, Steele Trenise, Selders Dwight, Tonsfeldt Jessica, Valardi Shelly, Fish Gary Edd, Aguado Hank A., Arceneaux Sally, Arnwine Jean, Bell Kim, Bell Tina, Boleman Bob, Bradley Patricia, Callanan David, Coors Lori, Creighton Jodi, Crew Timothy, Cummings Kimberly, Dock Christopher, Duignan Karen, Fuller Dwain, Gray Keith, Hendrix Betsy, Hesse Nicholas, Jaramillo Diana, Jost Bradley, Lash Sandy, Lonsdale Laura, Mackens Michael, Mut, "Outcomes of Eyes with Lesions Composed of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)", Ophthalmology, AMSTERDAM, NL, (20150201), vol. 122, no. 2, doi:10.1016/j.ophtha.2014.08.020, ISSN 0161-6420, pages 391 - 398.e5, XP055895128
OPPOSITION- Altaweel Michael M., Daniel Ebenezer, Martin Daniel F., Mittra Robert A., Grunwald Juan E., Lai Michael M., Melamud Alexander, Morse Lawrence S., Huang Jiayan, Ferris Frederick L., Fine Stuart L., Maguire Maureen G., Williams David F., Beardsley Sara, Bennett Steven, Cantrill Herbert, Chan- Tram Carmen, Cheshier Holly, Damato Kathyrn, Davies John, Dev Sundeep, Enloe Julianne, Follano Gennaro, Gilbert Peggy, Johnson Jill, Jones Tori, Mayleben Lisa, Moos Martha, Neist Ryan, Oestreich Neal, Quiram Polly, Ramsay Robert, Ryan Edwin, Schindeldecker Stephanie, Snater John, Steele Trenise, Selders Dwight, Tonsfeldt Jessica, Valardi Shelly, Fish Gary Edd, Aguado Hank A., Arceneaux Sally, Arnwine Jean, Bell Kim, Bell Tina, Boleman Bob, Bradley Patricia, Callanan David, Coors Lori, Creighton Jodi, Crew Timothy, Cummings Kimberly, Dock Christopher, Duignan Karen, Fuller Dwain, Gray Keith, Hendrix Betsy, Hesse Nicholas, Jaramillo Diana, Jost Bradley, Lash Sandy, Lonsdale Laura, Mackens Michael, Mut, "Outcomes of Eyes with Lesions Composed of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)", Ophthalmology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20150201), vol. 122, no. 2, doi:10.1016/j.ophtha.2014.08.020, ISSN 0161-6420, pages 391 - 398.e5, XP055895128
OPPOSITION- Evans Rebecca N., Reeves Barnaby C., Phillips Dawn, Muldrew Katherine Alyson, Rogers Chris, Harding Simon P., Chakravarthy Usha, "Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial", Ophthalmology, AMSTERDAM, NL, (20200901), vol. 127, no. 9, doi:10.1016/j.ophtha.2020.03.020, ISSN 0161-6420, pages 1191 - 1200, XP093131135
OPPOSITION- K H Patel, C C Chow, R Rathod, W F Mieler, J I Lim, L J Ulanski, Y I Leiderman, V Arun, F Y Chau, "Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab", Eye, (20130501), vol. 27, no. 5, doi:10.1038/eye.2013.31, ISSN 0950222X, pages 663 - 668, XP055138985
OPPOSITION- Grewal D S, Gill M K, Sarezky D, Lyon A T, Mirza R G, "Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results", EYE, Nature Publishing Group, GB, GB , (20140701), vol. 28, no. 7, doi:10.1038/eye.2014.101, ISSN 0950-222X, pages 895 - 899, XP055973186
OPPOSITION- ROSENFELD PHILIP J ET AL, "Ranibizumab for neovascular age-related macular degeneration", The New England journal of medicine, Massachusetts Medical Society, US, US , (20061005), vol. 355, no. 14, doi:10.1056/NEJMoa054481, ISSN 0028-4793, pages 1419 - 1431, XP002506588
OPPOSITION- Teng‐teng Yao; Yuan Yang; Xiao‐liang Jin; Yi‐xiao Wang; Ya‐li Zhou; A‐jing Xu; Fang‐lin He; Zhao‐yang Wang, "Intraocular pharmacokinetics of anti‐vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil‐filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study", Acta Ophthalmologica: the ophthalmological journal of the Nordic countries, Wiley-Blackwell Munksgaard, Denmark, Denmark , (20200229), vol. 98, no. 7, doi:10.1111/aos.14386, ISSN 1755-375X, pages e795 - e800, XP072397594
OPPOSITION- Ursula Schmidt-Erfurth, Victor Chong, Anat Loewenstein, Michael Larsen, Eric Souied, Reinier Schlingemann, Bora Eldem, Jordi Monés, Gisbert Richard, Francesco Bandello, "Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)", BRITISH JOURNAL OF OPHTHALMOLOGY, BMJ Publishing Group, GB, GB , (20140901), vol. 98, no. 9, doi:10.1136/bjophthalmol-2014-305702, ISSN 0007-1161, pages 1144 - 1167, XP055404243
OPPOSITION- Ursula Schmidt-Erfurth, Victor Chong, Anat Loewenstein, Michael Larsen, Eric Souied, Reinier Schlingemann, Bora Eldem, Jordi Monés, Gisbert Richard, Francesco Bandello, "Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)", BRITISH JOURNAL OF OPHTHALMOLOGY, GB , (20140901), vol. 98, no. 9, doi:10.1136/bjophthalmol-2014-305702, ISSN 0007-1161, pages 1144 - 1167, XP055404243
OPPOSITION- Gillies Mark C., Walton Richard, Simpson Judy M., Arnold Jennifer J., Guymer Robyn H., Mcallister Ian L., Hunyor Alex P., Essex Rohan W., Morlet Nigel, Barthelmes Daniel, "Prospective Audit of Exudative Age-Related Macular Degeneration: 12-Month Outcomes in Treatment-Naïve Eyes", Investigative Opthalmology & Visual Science, Association for Research in Vision and Ophthalmology, US, US , (20130827), vol. 54, no. 8, doi:10.1167/iovs.13-11993, ISSN 1552-5783, pages 5754 - 5760, XP055973149
OPPOSITION- M. OHR et al., "Aflibercept in wet age-related macular degeneration: a perspective review", Therapeutic Advances in Chronic Disease, (20120000), doi:10.1177/2040622312446007, pages 153 - 161, XP055895121
OPPOSITION- Ohr Matthew, Kaiser Peter K., "Aflibercept in wet age-related macular degeneration: a perspective review", Therapeutic Advances in Chronic Disease2011SAGE Publications Ltdgbr, (20120701), vol. 3, no. 4, doi:10.1177/2040622312446007, ISSN 2040-6223, pages 153 - 161, XP055895121
OPPOSITION- Ohr Matthew, Kaiser Peter K., "Aflibercept in wet age-related macular degeneration: a perspective review", Therapeutic Advances in Chronic Disease, (20120701), vol. 3, no. 4, doi:10.1177/2040622312446007, ISSN 2040-6223, pages 153 - 161, XP055895121
OPPOSITION- Jain Sachin, Kishore Kamal, Sharma Yograj, "Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration", Indian Journal of Ophthalmology, IN , (20130901), vol. 61, no. 9, doi:10.4103/0301-4738.119432, ISSN 0301-4738, pages 490 - 496, XP055973576

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents